Expert Opinions on Uveal Melanoma: Insights from the 58th Ophthalmic Oncology Group Meeting [0.03%]
眼癌组第58次会议上关于葡萄膜黑色素瘤的专家意见及见解
Gustav Stålhammar,Vicktoria Vishnevskia-Dai,Robert M Verdijk et al.
Gustav Stålhammar et al.
Introduction: Clear evidence for the best clinical management of uveal melanoma is lacking in some areas. Therefore, reports on expert opinions in the field can be valuable. ...
Intraocular Surgery for Retinoblastoma: An Evaluation of Current Evidence [0.03%]
视网膜母细胞瘤玻璃体内注射现状及证据分析
Sam Peter Gurney,Joseph Abbott,Gerard Millen et al.
Sam Peter Gurney et al.
Background: Retinoblastoma (Rb) is the most common intraocular malignancy of childhood. The prognosis in Rb directly relates to the spread of disease beyond the eye, particularly to the central nervous system. Therefore, ...
Ruthenium-106 Plaque Brachytherapy for Circumscribed Choroidal Hemangioma: A Case Series and Review of Literature [0.03%]
ruthenium-106 放疗治疗脉络膜血管瘤的病例报道及文献回顾
Islam Y Swaify,Hany Hamza,Ayman M Khattab et al.
Islam Y Swaify et al.
Introduction: We aim to report the anatomical and functional outcomes of ruthenium-106 brachytherapy in the management of circumscribed choroidal hemangiomas (CCH). ...
How Much Time Do Focal Treatments for Retinoblastoma Add to Anesthetic Exposure? [0.03%]
焦点治疗视网膜母细胞瘤所增加的麻醉暴露时间有多少？
David H Abramson,Jacquelyn Gaccione,Christina Bracken et al.
David H Abramson et al.
Introduction: Children with retinoblastoma have anesthesia for exams and treatment, but there is little information about how long treatment interventions (laser, cryotherapy, and intravitreal injections) add to routine e...
Subretinal Exudation: The First Presentation of Untreated Choroidal Melanomas [0.03%]
脉外渗出性改变为未治疗脉络膜黑色素瘤的首发症状
Asterios Diafas,Harriet Williams,Ayodeji Ajanaku et al.
Asterios Diafas et al.
Introduction: This case series aims to present the unusual clinical manifestation of subretinal exudation in patients diagnosed with untreated choroidal melanoma. A total of 886 patients were diagnosed and treated for pri...
Adjuvant Brachytherapy with Ruthenium-106 to Reduce the Risk of Recurrence of Conjunctival Melanoma after Excision [0.03%]
术后降低结膜黑色素瘤复发风险的-106后装治疗辅助疗法
Luise Grajewski,Christiane Kneifel,Markus Wösle et al.
Luise Grajewski et al.
Introduction: Local recurrence of conjunctival melanoma (CM) is common after excision. Local radiotherapy is an effective adjuvant treatment option, and brachytherapy with ruthenium-106 (106Ru) is one such option. Thus, h...
Clinicopathologic Features of Eyelid Sebaceous Gland Carcinoma Requiring Immunohistochemical Diagnosis [0.03%]
需要免疫组化诊断的眼睑皮脂腺癌临床病理特征分析
Tatsuya Yunoki,Akio Miyakoshi,Atsushi Hayashi
Tatsuya Yunoki
Introduction: The aim of the study was to evaluate the clinicopathological features of eyelid sebaceous gland carcinoma (SGC), which requires immunohistochemical examination for a definitive diagnosis. ...
Neoadjuvant Chemotherapy in Non-Metastatic Eyelid Sebaceous Gland Carcinoma: A Report in 10 Cases [0.03%]
非转移性睑板腺癌新辅助化疗：10例报告
Nipun Kumar,Rachna Meel,Sameer Bakhshi et al.
Nipun Kumar et al.
Introduction: Eyelid sebaceous gland carcinoma (SGC) is an aggressive malignancy. Surgical excision is the standard treatment for non-metastatic eyelid SGC. This study aimed to evaluate treatment outcomes with use of neoa...
Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature [0.03%]
贝扎图滨治疗von Hippel-Lindau病性视网膜血管瘤的机构经验及文献综述
Farzad Jamshidi,Lola Lozano,Budd Tucker et al.
Farzad Jamshidi et al.
Introduction: The systemic HIF-2 alpha inhibitor, belzutifan, has been approved for use in patients with von Hippel-Lindau disease (VHL)-associated renal cell carcinoma, central nervous system (CNS) hemangioblastomas, and...
Talisa E de Carlo Forest,Scott C N Oliver
Talisa E de Carlo Forest
Introduction: The aim of the study was to describe and evaluate characteristics of ocular tumor lysis syndrome (OTLS) in eyes with uveal melanoma. Methods...